Prediction: Eli Lilly Will Be Worth More Than Berkshire Hathaway by 2030

Eli Lilly is projected for significant medium-term outperformance through 2030, driven by its dominant position in the rapidly expanding weight management drug market with products like Zepbound and a robust pipeline including oral GLP-1 orforglipron and triple-agonist retatrutide, potentially allowing it to surpass Berkshire Hathaway's market capitalization. Conversely, Berkshire Hathaway faces headwinds from its impending leadership transition post-Warren Buffett and challenges impacting its largest holding, Apple, which constitutes over a fifth of its portfolio, suggesting a more subdued performance despite its long-term investment philosophy.

Analysis

Eli Lilly (LLY) presents a compelling medium-term growth outlook through 2030, primarily driven by its dominant position in the rapidly expanding weight management drug market. Its tirzepatide (Zepbound) is fueling fast-growing sales, complemented by a robust pipeline featuring orforglipron, a potential oral GLP-1, and retatrutide, a triple-agonist whose Phase 2 efficacy was compared to bariatric surgery, positioning LLY to potentially surpass Berkshire Hathaway's $1 trillion market cap within five years from its current $800 billion.

Conversely, Berkshire Hathaway (BRK.A/B) faces significant headwinds that could temper its performance through the decade. The impending departure of Warren Buffett as CEO introduces leadership uncertainty, requiring new CEO Greg Abel to prove himself to investors.

Furthermore, Berkshire's largest holding, Apple (AAPL), which constitutes over a fifth of its $257.2 billion portfolio, is contending with tariffs impacting profits and increased competition from trillion-dollar tech peers in the artificial intelligence market. While Berkshire maintains long-term value through diversification and investment philosophy, its near-term performance is expected to be subdued compared to Lilly's projected outperformance through 2030.

Key Decisions for Investors

• Investors should evaluate Eli Lilly's strong growth trajectory, fueled by its leading position in the weight management drug market and promising pipeline, as a potential outperformer through 2030.
• Monitor Berkshire Hathaway's leadership transition and the performance of its significant Apple holding, as these factors present near-term uncertainties and potential limitations to upside.
• Consider a strategic allocation that balances Eli Lilly's high-growth potential against Berkshire Hathaway's long-term value proposition, acknowledging that BRK may require more patience for market-beating returns.